FOLH1 and prostate carcinoma: Although 177Lu-PSMA-617 is not necessarily selected for all the patients described above, it is certain that the demand for nuclear medicine therapy for prostate cancer patients will significantly increase given that the indications for this therapy are expected to expand beyond metastatic castration-resistant prostate cancer and that other nuclear medicine therapies for advanced prostate cancer are expected to be introduced [6, 7].